en · de · es · pt
melanotan-2-notes.peptides3626.com › Data › Melanotan-2 Identity And Receptor Pharmacology — Deep Dive

Melanotan-2 Identity And Receptor Pharmacology — Deep Dive

By Editorial Desk · published 2025-10-01 · last reviewed 2025-11-02 · Data

A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Related pages on this site

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Background from the literature

== Early life and education == Culp was born on August 16, 1930, in either Oakland, California, or Berkeley, California. He was the only child of Crozier Cordell Culp, an attorney, and his wife, Bethel Martin Culp (née Collins). He graduated from Berkeley High School, where he was a pole vaulter and took second place at the 1947 CIF California State Meet. Culp attended the University of the Pacific in Stockton, California, and later Washington University in St. Louis, San Francisco State, and the University of Washington School of Drama, but never completed an academic degree. He also received acting training at HB Studio in New York City.

Rasburicase, sold under the brand name Elitek in the US and Fasturtec in the EU, is a medication that helps to clear uric acid from the blood. It is a recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin. Urate oxidase is known to be present in many mammals but does not naturally occur in humans. Rasburicase is produced by a genetically modified Saccharomyces cerevisiae strain. The complementary DNA (cDNA) coding for rasburicase was cloned from a strain of Aspergillus flavus. Rasburicase (Q00511) is a tetrameric protein with identical subunits. Each subunit is made up of a single 301 amino acid polypeptide chain with a molecular mass of about 34 kDa. The drug product is a sterile, white to off-white, lyophilized powder intended for intravenous administration following reconstitution with a diluent. Elitek (rasburicase) is supplied in 3 mL and 10 mL colorless, glass vials containing rasburicase at a concentration of 1.5 mg/mL after reconstitution. It is on the World Health Organization's List of Essential Medicines.

Consumption of these peaks during cultural festivities such as the Mongolian lunar new year (in spring). The time of this celebration is called the "white month", which indicates that milk products (called "white food" together with starchy vegetables, in comparison to meat products, called "black food") are a central part of this tradition. The purpose of these festivities is to "close" the past year – clean the house or the yurt, honor the animals for having provided their food, and prepare everything for the coming summer season – to be ready to "open" the new year. Consuming white food in this festive context is a way to connect to the past and to a national identity, which is the Mongol Empire personified by Genghis Khan. During the time of this empire, the fermented mare milk was the drink to honor and thank warriors and leading persons, it was not meant for everybody. Although it eventually became a drink for normal people, it has kept its honorable meaning. Like many other traditions, this one feels the influence of globalization. Other products, like industrial yogurt, coming mainly from China and western countries, have tended to replace it more and more, mainly in urban areas. However, in rural and poorer regions it is still of great importance. Although this chemical process had been used in food production for thousands of years, the mechanism of microbial lactic acid fermentation was not understood until much later. During the 19th century, several chemists discovered some fundamental concepts of organic chemistry.

=== Cyanobacteria and the evolution of photosynthesis === The biochemical capacity to use water as the source for electrons in photosynthesis evolved once, in a common ancestor of extant cyanobacteria (formerly called blue-green algae). The geological record indicates that this transforming event took place early in Earth's history, at least 2450–2320 million years ago (Ma), and, it is speculated, much earlier. Because the Earth's atmosphere contained almost no oxygen during the estimated development of photosynthesis, it is believed that the first photosynthetic cyanobacteria did not generate oxygen. Available evidence from geobiological studies of Archean (>2500 Ma) sedimentary rocks indicates that life existed 3500 Ma, but the question of when oxygenic photosynthesis evolved is still unanswered. A clear paleontological window on cyanobacterial evolution opened about 2000 Ma, revealing an already-diverse biota of cyanobacteria. Cyanobacteria remained the principal primary producers of oxygen throughout the Proterozoic Eon (2500–543 Ma), in part because the redox structure of the oceans favored photoautotrophs capable of nitrogen fixation. Green algae joined cyanobacteria as the major primary producers of oxygen on continental shelves near the end of the Proterozoic, but only with the Mesozoic (251–66 Ma) radiations of dinoflagellates, coccolithophorids, and diatoms did the primary production of oxygen in marine shelf waters take modern form.

=== Mexico === In Mexico, Whirlpool has 5 manufacturing plants; three facilities in Apodaca, Nuevo León (including Supsa, Plastics Apodaca, and Horizon) producing refrigerators and washing machines, one facility in Celaya, Guanajuato producing stoves, compact refrigerators, and semi-automatic washing machines, and one facility in Ramos Arizpe, Coahuila producing duplex and French-door refrigerators. On July 1, 2026, Whirlpool announced it will close its Supsa refrigerator manufacturing plant in Apodaca, Mexico, by the second quarter of 2027, shifting production to its facility in Ramos Arizpe and other regional sites.

Sources: en.wikipedia.org

Reference notes

A group or series of case reports involving patients who were given similar treatment. Reports of case series usually contain detailed information about the individual patients. This includes demographic information (for example, age, gender, ethnic origin) and information on diagnosis, treatment, response to treatment, and follow-up after treatment. (NCI) Case-control study

==== pVI ==== pVI has been widely used for the display of cDNA libraries. The display of cDNA libraries via phage display is an attractive alternative to the yeast-2-hybrid method for the discovery of interacting proteins and peptides due to its high throughput capability. pVI has been used preferentially to pVIII and pIII for the expression of cDNA libraries because one can add the protein of interest to the C-terminus of pVI without greatly affecting pVI's role in phage assembly. This means that the stop codon in the cDNA is no longer an issue. However, phage display of cDNA is always limited by the inability of most prokaryotes in producing post-translational modifications present in eukaryotic cells or by the misfolding of multi-domain proteins. While pVI has been useful for the analysis of cDNA libraries, pIII and pVIII remain the most utilized coat proteins for phage display.

ångström (Å) A non-SI, metric unit of length equal to 10−10 metre, i.e. 1⁄10000000000 of a metre or 0.1 nanometre. The angstrom is commonly used in the natural sciences to express microscopic or atomic-scale distances, including the sizes of atomic nuclei, wavelengths of electromagnetic radiation, and lengths of chemical bonds (e.g. the covalent radius of a chlorine atom averages about 1 angstrom).

For voluntary and charitable services to the community in Limavady, County Londonderry. David Gregory Snook. Reading Volunteer, Hampton Primary School, Herne Bay, Kent. For services to Education. Versha Sood-Mahindra. Lately Dementia Lead, BUPA. For services to Community Cohesion and to People with Dementia in Cardiff. Zoe Donna Sookun. Project Manager, Network Rail. For services to the Railway and to Rail Aid for Ukraine. Denise Speight. Chargehand Cleaner, Newcastle City Council. For services to Local Government. Charlotte Jessica Stacey. On Call Firefighter, Oxfordshire Fire and Rescue Service. For services to the community in Oxfordshire. Margaret Pearl Sterling. Teaching Associate, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast. For services to Higher Education in Northern Ireland. Eileen Linda Stewart. Manager, Armagh Business Centre. For services to Entrepreneurship, to Economic Regeneration and to the community in Armagh, Northern Ireland. Gloria Ann Stewart. For services to the community in Sheffield, South Yorkshire. Sheena Stewart. Lately Warden, Chalmers Court Sheltered Housing Complex, Inverarary. For services to the community in Mid-Argyll. Allan Stokoe. For services to the community in Eldon, North Yorkshire. Dr Jill Mary Stoner. Chair, Cromarty Care Project. For services to the community in Cromarty, Ross and Cromarty. Jan Tallis. Founding Chair, Community Schools Trust. For services to Children and Families in the London Borough of Newham. Robert Sherwin Taylor. For services to the community in Shipbourne, Kent.

Sources: en.wikipedia.org

Notes from published material

A pariah field, cast out by the scientific establishment. Between cold fusion and respectable science there is virtually no communication at all. Cold fusion papers are almost never published in refereed scientific journals, with the result that those works don't receive the normal critical scrutiny that science requires. On the other hand, because the Cold-Fusioners see themselves as a community under siege, there is little internal criticism. Experiments and theories tend to be accepted at face value, for fear of providing even more fuel for external critics, if anyone outside the group was bothering to listen. In these circumstances, crackpots flourish, making matters worse for those who believe that there is serious science going on here.

The 2007 pet food recalls involved the massive recall of many brands of cat and dog foods beginning in March 2007. The recalls came in response to reports of renal failure in pets consuming mostly wet pet foods made with wheat gluten from a single Chinese company, beginning in February 2007. After more than three weeks of complaints from consumers, the recall began voluntarily with the Canadian company Menu Foods on March 16, 2007, when a company test showed sickness and death in some of the test animals. Overall, several major companies recalled more than 100 brands of pet foods, with most of the recalled product coming from Menu Foods. The contaminant was identified as melamine, which had been added as an adulterant to simulate a higher protein content. In the United States, there has been extensive media coverage of the recall. There have been calls for government regulation of pet foods, which had previously been self-regulated by pet food manufacturers. The economic impact on the pet food market has been extensive, with Menu Foods losing roughly $30 million alone from the recall.

=== Subjective and objective well-being === Subjective well-being is the measure of how people feel about and evaluate their lives, encompassing both affective and cognitive components. A person has high affective well-being if they have many pleasant experiences and few unpleasant ones. High cognitive well-being occurs when a person evaluates their life positively, making a global assessment that things are going well. Subjective well-being is measured using questionnaires in which individuals report the quality of their experiences. Single-item measures provide the simplest approach, focusing on a single scale, such as asking participants to rate how content they are with their lives on a scale from 1 to 10. Multi-item scales include questions for distinct aspects of subjective well-being, with the advantage of reducing the influence of the wording of any single question. They have separate questions for domains such as the presence of positive affect, the absence of negative affect, and overall life satisfaction, which they combine into a comprehensive index. Objective well-being encompasses objective factors indicating that a person's life is going well. Unlike subjective well-being, these factors can be assessed and quantified from an external perspective. They include personal, social, economic, and environmental aspects such as health, level of education, income, housing, amount of leisure, and security. By relying on objective data, measures of objective well-being are less affected by cultural and personal biases that can influence self-reports.

== Mechanism of action == T3 and T4 bind to nuclear receptors (thyroid hormone receptors). T3 and T4, although being lipophilic, are not able to passively diffuse through the phospholipid bilayers of target cells, instead relying on transmembrane iodothyronine transporters. The lipophilicity of T3 and T4 requires their binding to the protein carrier thyroid-binding protein (TBG) (thyroxine-binding globulins, thyroxine binding prealbumins, and albumins) for transport in the blood. The thyroid receptors bind to response elements in gene promoters, thus enabling them to activate or inhibit transcription. The sensitivity of a tissue to T3 is modulated through the thyroid receptors.

== History == The FDA's approval of sildenafil in 1998 was a ground-breaking commercial event for the treatment of ED, with sales exceeding US$1 billion. Subsequently, the FDA approved both vardenafil and tadalafil in 2003. It initially was developed by the biotechnology company ICOS, and then again developed and marketed worldwide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. Tadalafil was approved in 2009 in the United States for the treatment of pulmonary arterial hypertension and is under regulatory review in other regions for this condition. In late November 2008, Eli Lilly sold the exclusive rights to commercialize tadalafil for pulmonary arterial hypertension in the United States to United Therapeutics for an upfront payment of $150 million. Tadalafil was discovered by Glaxo Wellcome (now GlaxoSmithKline) under a partnership between Glaxo and ICOS to develop new drugs that began in August 1991. In 1993, the Bothell, Washington, biotechnology company ICOS Corporation began studying compound IC351, a phosphodiesterase type 5 (PDE5) enzyme inhibitor. In 1994, Pfizer scientists discovered that sildenafil, which also inhibits the PDE5 enzyme, caused penile erection in males participating in a clinical study of a heart medicine. Although ICOS scientists were not testing compound IC351 for treating ED, they recognized its potential usefulness for treating that disorder. Soon, in 1994, ICOS received a patent for compound IC351 (structurally unlike sildenafil and vardenafil), and Phase 1 clinical trials began in 1995.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

Network